BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11249551)

  • 1. Olanzapine: an atypical antipsychotic for schizophrenia.
    Lund BC; Perry PJ
    Expert Opin Pharmacother; 2000 Jan; 1(2):305-23. PubMed ID: 11249551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
    Bever KA; Perry PJ
    Am J Health Syst Pharm; 1998 May; 55(10):1003-16. PubMed ID: 9606451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical efficacy of olanzapine].
    Yui K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1999 Jul; 19(3):101-10. PubMed ID: 10495984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.
    Kando JC; Shepski JC; Satterlee W; Patel JK; Reams SG; Green AI
    Ann Pharmacother; 1997 Nov; 31(11):1325-34. PubMed ID: 9391688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine.
    Hale AS
    Br J Hosp Med; 1997 Nov 5-18; 58(9):442-5. PubMed ID: 9619205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.
    Fulton B; Goa KL
    Drugs; 1997 Feb; 53(2):281-98. PubMed ID: 9028746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of olanzapine for elderly patients with psychotic disorders: a review.
    Madhusoodanan S; Sinha S; Brenner R; Gupta S; Bogunovic O
    Ann Clin Psychiatry; 2001 Dec; 13(4):201-13. PubMed ID: 11958362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events related to olanzapine.
    Conley RR; Meltzer HY
    J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.
    Carlson CD; Cavazzoni PA; Berg PH; Wei H; Beasley CM; Kane JM
    J Clin Psychiatry; 2003 Aug; 64(8):898-906. PubMed ID: 12927004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone versus other atypical antipsychotic medication for schizophrenia.
    Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
    Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.